Extracorporeal Membrane Oxygenation Machines Market by Modality and Geography - Forecast and Analysis 2020-2024

体外膜酸素化装置の世界市場:予測及び分析 2020-2024

◆タイトル:Extracorporeal Membrane Oxygenation Machines Market by Modality and Geography - Forecast and Analysis 2020-2024
◆商品コード:IRTNTR40185
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2019年11月
◆ページ数:155
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療装置
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥270,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥324,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

本レポートは、体外膜酸素化装置の市場実態を調査・分析し、エグゼクティブサマリー、レポートの範囲、市場状況、市場規模、ファイブフォース分析、顧客状況、地域別状況、治療法別(静脈および動静脈、静脈動脈)分析、意思決定フレームワーク、市場の要因と課題、市場動向、企業状況、企業分析を掲載しています。
・エグゼクティブサマリー
・レポートの範囲
・市場状況
・市場規模
・ファイブフォース分析
・顧客状況
・地域別状況
・体外膜酸素化装置の世界市場:治療法別(静脈および動静脈、静脈動脈)
・意思決定フレームワーク
・市場の要因と課題
・市場動向
・企業状況
・企業分析

Global Extracorporeal Membrane Oxygenation Machines Market: About this market
Technavio’s extracorporeal membrane oxygenation machines market analysis considers sales from veno-venous and arterio-venous; and veno-arterial modalities. Our study also finds the sales of extracorporeal membrane oxygenation machines in Asia, Europe, North America, and ROW. In 2019, the veno-venous and arterio-venous segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as growing cases of lung transplants will play a significant role in the veno-venous and arterio-venous segment to maintain its market position. Also, our global extracorporeal membrane oxygenation machines market report looks at factors such as increasing incidence of respiratory and heart failure, rising number of new product launches, and growing number of transplant procedures. However, high costs associated with cardiac and respiratory procedures, complications related to ECMO procedures, and frequent product recalls may hamper the growth of the extracorporeal membrane oxygenation machines industry over the forecast period.

Global Extracorporeal Membrane Oxygenation Machines Market: Overview
Increasing prevalence of respiratory and heart failure
Respiratory diseases such as COPD, ARDS, and pulmonary embolism affect a large number of people across the world every year. The rising prevalence of these diseases can be attributed to factors such as respiratory infections, smoking, and air pollution. Similarly, the prevalence of CVDs and other heart diseases such as ischemic heart disease, coronary heart disease, and myocardial infarctions has significantly increased over recent years. These factors have increased the number of emergency department visits, which has necessitated the need for immediate treatment. Extracorporeal membrane oxygenation machines are majorly used for reducing the chances of cardiac failure in people with CVDs. They are also used by healthcare professionals to help patients at the risk of sudden respiratory failure. Therefore, the increasing incidences of respiratory and heart failures will lead to the expansion of the global extracorporeal membrane oxygenation machines market at a CAGR of almost 5% during the forecast period.

Technological advances
The growing number of technological innovations has enabled a paradigm shift in the cost as well as the manageability of medical equipment. The launch of wearable devices has made patient monitoring much simpler and more cost-effective and has contributed to better patient adherence to health monitoring. Extracorporeal membrane oxygenation machines are majorly used in hospitals, clinics, and ASCs as a life-support device. They are majorly used by healthcare professionals during certain medical emergencies and surgical procedures. Technologically advanced and innovative devices are majorly used by clinicians for patients suffering from certain chronic conditions where support for the heart and lung is required. This development is expected to have a positive impact on the overall market growth.
For the detailed list of factors that will drive the global extracorporeal membrane oxygenation machines market during the forecast period 2019-2023, click here.

Competitive Landscape
With the presence of several major players, the global extracorporeal membrane oxygenation machines market is fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading extracorporeal membrane oxygenation machines manufacturers, that include ALung Technologies Inc., Eurosets Srl, Fresenius Medical Care AG & Co. KGaA, Getinge AB, LivaNova Plc, Medtronic Plc, MicroPort Scientific Corp., NIPRO Corp., OriGen Biomedical Inc., and Terumo Corp.
Also, the extracorporeal membrane oxygenation machines market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【資料の目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market characteristics
• Value chain analysis
• Market segmentation analysis
PART 04: MARKET SIZING
• Market sizing 2019
• Market size and forecast 2019-2024
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: CUSTOMER LANDSCAPE
PART 07: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2019-2024
• Europe – Market size and forecast 2019-2024
• Asia – Market size and forecast 2019-2024
• ROW – Market size and forecast 2019-2024
• Key leading countries
• Market opportunity
PART 08: MARKET SEGMENTATION BY MODALITY
• Market segmentation by modality
• Comparison by modality
• Veno-venous and arterio-venous – Market size and forecast 2019-2024
• Veno-arterial – Market size and forecast 2019-2024
• Market opportunity by modality
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Technological advances
• Mergers and acquisitions
• Business strategies in the market
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• ALung Technologies Inc.
• Eurosets Srl
• Fresenius Medical Care AG & Co. KGaA
• Getinge AB
• LivaNova Plc
• Medtronic Plc
• MicroPort Scientific Corp.
• NIPRO Corp.
• OriGen Biomedical Inc.
• Terumo Corp.
PART 14: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO


Exhibit 01: Global healthcare equipment market
Exhibit 02: Segments of global healthcare equipment market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Product overview
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2019
Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
Exhibit 10: Five forces analysis 2019
Exhibit 11: Five forces analysis 2024
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2019
Exhibit 18: Customer landscape
Exhibit 19: Market share by geography 2019-2024 (%)
Exhibit 20: Geographic comparison
Exhibit 21: North America – Market size and forecast 2019-2024 ($ millions)
Exhibit 22: North America – Year-over-year growth 2020-2024 (%)
Exhibit 23: Europe – Market size and forecast 2019-2024 ($ millions)
Exhibit 24: Europe – Year-over-year growth 2020-2024 (%)
Exhibit 25: Asia – Market size and forecast 2019-2024 ($ millions)
Exhibit 26: Asia – Year-over-year growth 2020-2024 (%)
Exhibit 27: ROW – Market size and forecast 2019-2024 ($ millions)
Exhibit 28: ROW – Year-over-year growth 2020-2024 (%)
Exhibit 29: Key leading countries
Exhibit 30: Market opportunity
Exhibit 31: Modality – Market share 2019-2024 (%)
Exhibit 32: Comparison by modality
Exhibit 33: Veno-venous and arterio-venous – Market size and forecast 2019-2024 ($ millions)
Exhibit 34: Veno-venous and arterio-venous – Year-over-year growth 2020-2024 (%)
Exhibit 35: Veno-arterial – Market size and forecast 2019-2024 ($ millions)
Exhibit 36: Veno-arterial – Year-over-year growth 2020-2024 (%)
Exhibit 37: Market opportunity by modality
Exhibit 38: Product launch details and market impact analysis
Exhibit 39: Product recalls
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Business strategies and their market impact analysis
Exhibit 42: Vendor landscape
Exhibit 43: Landscape disruption
Exhibit 44: Vendors covered
Exhibit 45: Vendor classification
Exhibit 46: Market positioning of vendors
Exhibit 47: ALung Technologies Inc. – Vendor overview
Exhibit 48: ALung Technologies Inc. – Product segments
Exhibit 49: ALung Technologies Inc. – Key offerings
Exhibit 50: ALung Technologies Inc. – Key customers
Exhibit 51: Eurosets Srl – Vendor overview
Exhibit 52: Eurosets Srl – Product segments
Exhibit 53: Eurosets Srl – Organizational developments
Exhibit 54: Eurosets Srl – Key offerings
Exhibit 55: Eurosets Srl – Key customers
Exhibit 56: Fresenius Medical Care AG & Co. KGaA – Vendor overview
Exhibit 57: Fresenius Medical Care AG & Co. KGaA – Business segments
Exhibit 58: Fresenius Medical Care AG & Co. KGaA – Organizational developments
Exhibit 59: Fresenius Medical Care AG & Co. KGaA – Geographic focus
Exhibit 60: Fresenius Medical Care AG & Co. KGaA – Segment focus
Exhibit 61: Fresenius Medical Care AG & Co. KGaA – Key offerings
Exhibit 62: Fresenius Medical Care AG & Co. KGaA – Key customers
Exhibit 63: Getinge AB – Vendor overview
Exhibit 64: Getinge AB – Business segments
Exhibit 65: Getinge AB – Organizational developments
Exhibit 66: Getinge AB – Geographic focus
Exhibit 67: Getinge AB – Segment focus
Exhibit 68: Getinge AB – Key offerings
Exhibit 69: Getinge AB – Key customers
Exhibit 70: LivaNova Plc – Vendor overview
Exhibit 71: LivaNova Plc – Business segments
Exhibit 72: LivaNova Plc – Organizational developments
Exhibit 73: LivaNova Plc – Geographic focus
Exhibit 74: LivaNova Plc – Segment focus
Exhibit 75: LivaNova Plc – Key offerings
Exhibit 76: LivaNova Plc – Key customers
Exhibit 77: Medtronic Plc – Vendor overview
Exhibit 78: Medtronic Plc – Business segments
Exhibit 79: Medtronic Plc – Organizational developments
Exhibit 80: Medtronic Plc – Geographic focus
Exhibit 81: Medtronic Plc – Segment focus
Exhibit 82: Medtronic Plc – Key offerings
Exhibit 83: Medtronic Plc – Key customers
Exhibit 84: MicroPort Scientific Corp. – Vendor overview
Exhibit 85: MicroPort Scientific Corp. – Business segments
Exhibit 86: MicroPort Scientific Corp. – Organizational developments
Exhibit 87: MicroPort Scientific Corp. – Geographic focus
Exhibit 88: MicroPort Scientific Corp. – Segment focus
Exhibit 89: MicroPort Scientific Corp. – Key offerings
Exhibit 90: MicroPort Scientific Corp. – Key customers
Exhibit 91: NIPRO Corp. – Vendor overview
Exhibit 92: NIPRO Corp. – Product segments
Exhibit 93: NIPRO Corp. – Geographic focus
Exhibit 94: NIPRO Corp. – Segment focus
Exhibit 95: NIPRO Corp. – Key offerings
Exhibit 96: NIPRO Corp. – Key customers
Exhibit 97: OriGen Biomedical Inc. – Vendor overview
Exhibit 98: OriGen Biomedical Inc. – Product segments
Exhibit 99: OriGen Biomedical Inc. – Organizational developments
Exhibit 100: OriGen Biomedical Inc. – Key offerings
Exhibit 101: OriGen Biomedical Inc. – Key customers
Exhibit 102: Terumo Corp. – Vendor overview
Exhibit 103: Terumo Corp. – Business segments
Exhibit 104: Terumo Corp. – Organizational developments
Exhibit 105: Terumo Corp. – Geographic focus
Exhibit 106: Terumo Corp. – Segment focus
Exhibit 107: Terumo Corp. – Key offerings
Exhibit 108: Terumo Corp. – Key customers
Exhibit 109: Validation techniques employed for market sizing
Exhibit 110: Definition of market positioning of vendors



【掲載企業】

ALung Technologies Inc., Eurosets Srl, Fresenius Medical Care AG & Co. KGaA, Getinge AB, LivaNova Plc, Medtronic Plc, MicroPort Scientific Corp., NIPRO Corp., OriGen Biomedical Inc., and Terumo Corp.

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[体外膜酸素化装置の世界市場:予測及び分析 2020-2024]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆